Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BGMDOTCMKTS:HMGNOTCMKTS:IPSEYOTCMKTS:RGDXQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMDBG Medicine$0.00$0.00▼$0.00N/A2.58250 shsN/AHMGNHemagen Diagnostics$0.00$0.00▼$0.00N/A1.36N/AN/AIPSEYIPSEN$29.05+1.4%$28.97$25.11▼$32.25$9.61B0.541,603 shs850 shsRGDXQResponse Genetics$0.00$0.00▼$0.00N/AN/AN/AN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMDBG Medicine0.00%0.00%0.00%-23.08%0.00%HMGNHemagen Diagnostics0.00%0.00%0.00%0.00%0.00%IPSEYIPSEN+0.21%-3.50%-0.51%+1.22%-6.44%RGDXQResponse Genetics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBGMDBG MedicineN/AN/AN/AN/AN/AN/AN/AN/AHMGNHemagen DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/AIPSEYIPSENN/AN/AN/AN/AN/AN/AN/AN/ARGDXQResponse GeneticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGMDBG Medicine 0.00N/AN/AN/AHMGNHemagen Diagnostics 0.00N/AN/AN/AIPSEYIPSEN 3.00BuyN/AN/ARGDXQResponse Genetics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IPSEY, BGMD, HMGN, and RGDXQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025IPSEYIPSENDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGMDBG MedicineN/AN/AN/AN/AN/AN/AHMGNHemagen DiagnosticsN/AN/AN/AN/AN/AN/AIPSEYIPSEN$3.87B2.52N/AN/AN/A∞RGDXQResponse GeneticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGMDBG MedicineN/AN/A0.00N/AN/AN/AN/AN/AN/AHMGNHemagen DiagnosticsN/AN/A0.00N/AN/AN/AN/AN/AN/AIPSEYIPSEN$374.30MN/A0.0010.09N/AN/AN/AN/A7/31/2025 (Estimated)RGDXQResponse GeneticsN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGMDBG MedicineN/AN/AN/AN/AN/AHMGNHemagen DiagnosticsN/AN/AN/AN/AN/AIPSEYIPSEN$0.260.90%N/AN/AN/ARGDXQResponse GeneticsN/AN/AN/AN/AN/ALatest IPSEY, BGMD, HMGN, and RGDXQ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/3/2025IPSEYIPSEN$0.28960.97%6/9/20256/10/20256/25/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGMDBG MedicineN/AN/AN/AHMGNHemagen DiagnosticsN/AN/AN/AIPSEYIPSENN/A1.341.15RGDXQResponse GeneticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGMDBG MedicineN/AHMGNHemagen DiagnosticsN/AIPSEYIPSENN/ARGDXQResponse GeneticsN/AInsider OwnershipCompanyInsider OwnershipBGMDBG Medicine6.50%HMGNHemagen Diagnostics36.50%IPSEYIPSENN/ARGDXQResponse Genetics4.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGMDBG Medicine5N/AN/ANot OptionableHMGNHemagen Diagnostics15N/AN/ANot OptionableIPSEYIPSEN5,325335.26 millionN/ANot OptionableRGDXQResponse Genetics100N/AN/ANot OptionableIPSEY, BGMD, HMGN, and RGDXQ HeadlinesRecent News About These CompaniesNew framework enhances genetic prediction of drug response and side effectsDecember 5, 2024 | msn.comGenetic variation enhances cancer drug sensitivity in specific patient groups, study showsNovember 14, 2024 | msn.comRefugee response plansNovember 14, 2024 | unhcr.orgDrug Combination Prompts Immune Response in Some Resistant Pancreatic CancersNovember 14, 2024 | msn.comNew cancer therapy strategy targets GLUT3 in regulatory T cells to supercharge anti-tumor immunityNovember 13, 2024 | msn.comCombining gene expression signature with liquid biopsy may improve response prediction to immunotherapyNovember 8, 2024 | medicalxpress.comRGI to build a second West Circle commercial complexNovember 6, 2024 | finance.yahoo.comEpigenetic silencing of a DNA damage repair gene reveals a potential marker for pancreatic cancer treatmentNovember 6, 2024 | msn.comPrecision exercise medicine: understanding exercise response variabilityNovember 6, 2024 | bjsm.bmj.comA 36-gene predictive score of anti-cancer drug resistance anticipates cancer therapy outcomesNovember 6, 2024 | uab.eduWrightbus expands refurbishment division with acquisition of GB firm RGINovember 6, 2024 | msn.comBetween night and day: Research uncovers genetic basis for flies' circadian plasticityNovember 1, 2024 | msn.comRGI Airport increases security after receiving bomb threats in three aircraftsOctober 30, 2024 | telanganatoday.comStudy uncovers six cancer susceptibility genesOctober 29, 2024 | msn.comIndigo Airlines Flights Alerted Amid Security Concerns at RGIOctober 28, 2024 | deccanchronicle.comGenetic Variants and Escitalopram Response in MDDOctober 22, 2024 | physiciansweekly.comHaryana Guv Dattratreya’s convoy collides at RGI airport, no injuries reportedOctober 20, 2024 | telanganatoday.comA faster, more affordable technique for deciphering the genetics of diseaseOctober 19, 2024 | msn.comSurprise finding reveals the dual role of key neurodevelopmental gene FOXG1October 18, 2024 | msn.comGenetic mapping study uncovers four main categories of cancer drug resistance mutationsOctober 18, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPSEY, BGMD, HMGN, and RGDXQ Company DescriptionsBG Medicine OTCMKTS:BGMDBG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.Hemagen Diagnostics OTCMKTS:HMGNHemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its human diagnostics products also comprise Universal IFA components; supplies, controls and calibrators, accessories, and H-rotors; reagents, electrodes, equipment; and specialty assays, including Chagas, acute phase proteins, and cytokines. In addition, the company provides veterinary diagnostic products, such as equipment, reagents, supplies, accessories, and electrodes in chemistry, hematology, and electrolyte areas. It sells its products directly, as well as through distributors to various laboratories, hospitals, and blood banks. The company was founded in 1985 and is based in Columbia, Maryland.IPSEN OTCMKTS:IPSEY$29.05 +0.40 (+1.38%) As of 06/24/2025 03:58 PM EasternIpsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.Response Genetics OTCMKTS:RGDXQResponse Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Insiders Chase Income and Stability in American Tower—Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
